Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Heterosexual male in a stable, monogamous, sexual relationship with a female partner for at least 6 months~* onset of orgasm and ejaculation occurs with minimal sexual stimulation before or shortly after penetration and before the person wishes it~* premature ejaculation (PE) in the majority of intercourse experiences in the 6 months before study initiation~* intravaginal latency ejaculatory time (IELT) of \<=2 minutes in at least 3 out of 4 events~* participants with partners of child-bearing potential must consent to use a medically acceptable method of contraception throughout the entire study~* participant's partner must have a negative pregnancy test at time of screening.~Exclusion Criteria:~* History of surgery or injury to the pelvis or spinal cord, chronic inflammation of the prostate or urethra~* taking medications that are contraindicated for participation in the study~* currently using other forms of therapy for treatment of PE (for example, behavioral therapy or medications applied locally)~* previously participated in a drug study involving dapoxetine or in another drug trial within the last month~* taken pimozide, astemizole, or monoamine oxidase inhibitors within 6 months of the start of the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).